azathioprine has been researched along with Hepatitis C in 56 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A recent report noted that cyclosporine (CsA) inhibits replication of the hepatitis C virus (HCV) in vitro." | 7.73 | Retrospective study of the effects of cyclosporine in comparison with azathioprine on renal transplant recipients infected with hepatitis C virus. ( Arichi, N; Fujii, N; Ichikawa, Y; Kishikawa, H; Kyo, M; Nishikawa, M; Nishimura, K; Tokugawa, S; Yoshioka, I, 2006) |
| " Some histopathological features consistent with azathioprine hepatotoxicity like cholestasis, perisinusoidal fibrosis, veno-subocclusive lesions and nodular regenerative hyperplasia were also observed in this case." | 7.70 | Hepatitis C virus-related fibrosing cholestatic hepatitis after cardiac transplantation: is azathioprine a contributory factor? ( Aguado, JM; Colina, F; Delgado, J; Fuertes, A; Gomez, MA; Ibarrola, C; Morales, JM; Muñoz de Bustillo, E; Rodriguez, E, 1999) |
| "To determine adverse events of ribavirin in the treatment of chronic hepatitis C, 41 patients (18 with cirrhosis), treated with ribavirin at an initial dose of 600-1200mg day(-1), were analysed retrospectively (six patients were treated twice because adverse effects during the first treatment necessitated cessation of ribavirin)." | 7.69 | Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin. ( Blot, C; Mathurin, P; Moussalli, J; Opolon, P; Perrin, M; Plassart, F; Poynard, T; Thevenot, T, 1997) |
| "Tacrolimus monotherapy is a viable immunosuppressive strategy in HCV-infected liver transplant recipients." | 6.72 | Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis. ( Burroughs, AK; Davidson, BR; Dhillon, AP; Leandro, G; Mela, M; Patch, DW; Pesci, A; Quaglia, A; Raimondo, ML; Rolles, K; Samonakis, DN; Thalheimer, U; Triantos, CK, 2006) |
| "Hepatitis C virus (HCV) recurrence in HCV+ liver transplant recipients is almost inevitable and may be promoted by immunosuppression." | 6.71 | Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. ( Agnes, S; Burra, P; Callea, F; De Carlis, L; Fassati, LR; Ferrara, R; Filipponi, F; Grazi, GL; Pisati, R; Risaliti, A; Rossi, M; Salizzoni, M; Valente, U, 2004) |
| "Amantadine was given orally (200 mg/d) for 3 months." | 5.33 | Amantadine monotherapy is ineffective in the treatment of hepatitis C virus recurrence in the post-liver transplantation setting. ( Angelico, M; Anselmo, A; D'Andria, D; de Liguori Carino, N; de'Liguori Carino, N; Ielpo, B; Manzia, T; Muzi, F; Orlando, G; Sabato Ceraldi, S; Tariciotti, L; Tisone, G, 2005) |
| " We present what we believe to be the first case of primary esophageal lymphoma in a patient on long-term immunosuppression with azathioprine who was also infected with the hepatitis C virus (HCV)." | 4.81 | Primary lymphoma of the esophagus in a chronically immunosuppressed patient with hepatitis C infection: case report and review of the literature. ( Golioto, M; McGrath, K, 2001) |
| "Because of the fibrosing alveolitis associated with hepatitis C-related cryoglobulinemia, immunosuppression was started with high-dosage prednisone and azathioprine." | 3.74 | [Fibrosing alveolitis with hepatitis C-related cryoglobulinemia]. ( Dalhoff, K; Heyer, P; Rupp, J; Schaaf, B; Witte, L, 2008) |
| "A recent report noted that cyclosporine (CsA) inhibits replication of the hepatitis C virus (HCV) in vitro." | 3.73 | Retrospective study of the effects of cyclosporine in comparison with azathioprine on renal transplant recipients infected with hepatitis C virus. ( Arichi, N; Fujii, N; Ichikawa, Y; Kishikawa, H; Kyo, M; Nishikawa, M; Nishimura, K; Tokugawa, S; Yoshioka, I, 2006) |
| " Some histopathological features consistent with azathioprine hepatotoxicity like cholestasis, perisinusoidal fibrosis, veno-subocclusive lesions and nodular regenerative hyperplasia were also observed in this case." | 3.70 | Hepatitis C virus-related fibrosing cholestatic hepatitis after cardiac transplantation: is azathioprine a contributory factor? ( Aguado, JM; Colina, F; Delgado, J; Fuertes, A; Gomez, MA; Ibarrola, C; Morales, JM; Muñoz de Bustillo, E; Rodriguez, E, 1999) |
| "To determine adverse events of ribavirin in the treatment of chronic hepatitis C, 41 patients (18 with cirrhosis), treated with ribavirin at an initial dose of 600-1200mg day(-1), were analysed retrospectively (six patients were treated twice because adverse effects during the first treatment necessitated cessation of ribavirin)." | 3.69 | Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin. ( Blot, C; Mathurin, P; Moussalli, J; Opolon, P; Perrin, M; Plassart, F; Poynard, T; Thevenot, T, 1997) |
| "Tacrolimus monotherapy is a viable immunosuppressive strategy in HCV-infected liver transplant recipients." | 2.72 | Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis. ( Burroughs, AK; Davidson, BR; Dhillon, AP; Leandro, G; Mela, M; Patch, DW; Pesci, A; Quaglia, A; Raimondo, ML; Rolles, K; Samonakis, DN; Thalheimer, U; Triantos, CK, 2006) |
| "Hepatitis C virus (HCV) recurrence in HCV+ liver transplant recipients is almost inevitable and may be promoted by immunosuppression." | 2.71 | Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. ( Agnes, S; Burra, P; Callea, F; De Carlis, L; Fassati, LR; Ferrara, R; Filipponi, F; Grazi, GL; Pisati, R; Risaliti, A; Rossi, M; Salizzoni, M; Valente, U, 2004) |
| "Chronic hepatitis C is a common cause of viral liver disease in kidney transplant (KT) recipients." | 2.68 | Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. ( Baron, E; Duffaut, M; Durand, D; Izopet, J; Puel, J; Rostaing, L, 1995) |
| "De novo autoimmune hepatitis (AIH) is an unusual cause of graft dysfunction after liver transplantation." | 2.58 | De novo autoimmune hepatitis -is this different in adults compared to children? ( Kerkar, N; Vergani, D, 2018) |
| "There is no difference in HCV recurrence between tacrolimus and cyclosporine regimens, but tacrolimus increases graft and patient survival in HCV transplanted patients." | 2.48 | Immunosuppression and HCV recurrence after liver transplantation. ( Burroughs, AK; Germani, G; Samonakis, DN, 2012) |
| "Among the rare cases of Sweet syndrome associated to a systemic inflammatory response syndrome that have been described there have not been any fatal cases as occurred with our patient." | 1.34 | [Fatal Sweet syndrome associated to chronic idiopathic systemic inflammatory response syndrome]. ( Almagro, M; del Pozo, J; Fonseca, E; Malmierca, NM; Martín, CG; Martínez, W; Yebra-Pimentel, MT, 2007) |
| "Amantadine was given orally (200 mg/d) for 3 months." | 1.33 | Amantadine monotherapy is ineffective in the treatment of hepatitis C virus recurrence in the post-liver transplantation setting. ( Angelico, M; Anselmo, A; D'Andria, D; de Liguori Carino, N; de'Liguori Carino, N; Ielpo, B; Manzia, T; Muzi, F; Orlando, G; Sabato Ceraldi, S; Tariciotti, L; Tisone, G, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (10.71) | 18.7374 |
| 1990's | 22 (39.29) | 18.2507 |
| 2000's | 20 (35.71) | 29.6817 |
| 2010's | 8 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kerkar, N | 1 |
| Vergani, D | 1 |
| Silva, J | 1 |
| Brito, BS | 1 |
| Silva, INN | 1 |
| Nóbrega, VG | 1 |
| da Silva, MCSM | 1 |
| Gomes, HDN | 1 |
| Fortes, FM | 1 |
| Pimentel, AM | 1 |
| Mota, J | 1 |
| Almeida, N | 1 |
| Surlo, VC | 1 |
| Lyra, A | 1 |
| Rocha, R | 1 |
| Santana, GO | 1 |
| Rosen, D | 1 |
| Chu, J | 1 |
| Morotti, R | 1 |
| Levanon, D | 1 |
| Rose, S | 1 |
| Lee, S | 1 |
| Arnon, R | 1 |
| Germani, G | 2 |
| Pleguezuelo, M | 1 |
| Villamil, F | 1 |
| Vaghjiani, S | 1 |
| Tsochatzis, E | 2 |
| Andreana, L | 1 |
| Burroughs, AK | 6 |
| Manousou, P | 2 |
| Samonakis, D | 1 |
| Cholongitas, E | 1 |
| Patch, D | 2 |
| O'Beirne, J | 2 |
| Dhillon, AP | 4 |
| Rolles, K | 3 |
| McCormick, A | 1 |
| Hayes, P | 1 |
| Manzia, TM | 1 |
| Di Paolo, D | 1 |
| Sforza, D | 1 |
| Toti, L | 1 |
| Angelico, R | 1 |
| Brega, A | 1 |
| Angelico, M | 3 |
| Tisone, G | 3 |
| Kim, RD | 1 |
| Fujikawa, T | 1 |
| Mizuno, S | 1 |
| Schwartz, JJ | 1 |
| Sorensen, JB | 1 |
| Hemming, AW | 1 |
| Fujita, S | 1 |
| Samonakis, DN | 3 |
| Chan, AJ | 1 |
| Lake, JR | 1 |
| Sochatzis, ET | 1 |
| Isgro, G | 1 |
| Hall, A | 1 |
| Green, A | 1 |
| Calvaruso, V | 1 |
| Ma, GL | 1 |
| Gale, J | 1 |
| Burgess, G | 1 |
| Thorburn, D | 1 |
| Leandro, G | 3 |
| Frustaci, A | 1 |
| Calabrese, F | 1 |
| Chimenti, C | 1 |
| Pieroni, M | 1 |
| Thiene, G | 1 |
| Maseri, A | 1 |
| Zekry, A | 1 |
| Gleeson, M | 1 |
| Guney, S | 1 |
| McCaughan, GW | 1 |
| Encke, J | 1 |
| Uhl, W | 1 |
| Stremmel, W | 1 |
| Sauer, P | 1 |
| Miller, EB | 1 |
| Friedman, JA | 1 |
| Kornberg, A | 1 |
| Küpper, B | 1 |
| Tannapfel, A | 1 |
| Hommann, M | 1 |
| Scheele, J | 1 |
| Filipponi, F | 1 |
| Callea, F | 2 |
| Salizzoni, M | 1 |
| Grazi, GL | 1 |
| Fassati, LR | 3 |
| Rossi, M | 1 |
| Risaliti, A | 1 |
| Burra, P | 1 |
| Agnes, S | 1 |
| De Carlis, L | 1 |
| Valente, U | 1 |
| Ferrara, R | 1 |
| Pisati, R | 1 |
| Féray, C | 1 |
| Triantos, CK | 2 |
| Thalheimer, U | 2 |
| Quaglia, A | 2 |
| Teixeira, R | 1 |
| Papatheodoridis, GV | 1 |
| Sabin, CA | 1 |
| Rolando, N | 1 |
| Davies, S | 1 |
| Griffiths, P | 1 |
| Emery, V | 1 |
| Patch, DW | 2 |
| Davidson, BR | 2 |
| Muzi, F | 1 |
| Orlando, G | 2 |
| Ielpo, B | 1 |
| Anselmo, A | 1 |
| Sabato Ceraldi, S | 1 |
| de Liguori Carino, N | 1 |
| de'Liguori Carino, N | 1 |
| Manzia, T | 1 |
| D'Andria, D | 1 |
| Tariciotti, L | 1 |
| Nagai, H | 1 |
| Matsumaru, K | 1 |
| Shiozawa, K | 1 |
| Momiyama, K | 1 |
| Wakui, N | 1 |
| Shinohara, M | 1 |
| Watanabe, M | 1 |
| Ishii, K | 1 |
| Nonaka, H | 1 |
| Hasegawa, A | 1 |
| Teramoto, T | 1 |
| Yamamuro, W | 1 |
| Sumino, Y | 1 |
| Miki, K | 1 |
| Mela, M | 1 |
| Pesci, A | 1 |
| Raimondo, ML | 1 |
| Ichikawa, Y | 2 |
| Kishikawa, H | 1 |
| Nishimura, K | 1 |
| Tokugawa, S | 1 |
| Yoshioka, I | 1 |
| Arichi, N | 1 |
| Fujii, N | 1 |
| Kyo, M | 2 |
| Nishikawa, M | 1 |
| del Pozo, J | 1 |
| Malmierca, NM | 1 |
| Yebra-Pimentel, MT | 1 |
| Almagro, M | 1 |
| Martínez, W | 1 |
| Martín, CG | 1 |
| Fonseca, E | 1 |
| Witte, L | 1 |
| Rupp, J | 1 |
| Heyer, P | 1 |
| Dalhoff, K | 1 |
| Schaaf, B | 1 |
| Auer, IO | 1 |
| Aprosina, ZG | 1 |
| Villa, E | 1 |
| Jenkins, P | 1 |
| Portmann, B | 1 |
| Eddleston, AL | 1 |
| Williams, R | 1 |
| Hanafusa, T | 1 |
| Fukunishi, T | 1 |
| Nagano, S | 1 |
| Nakayama, K | 1 |
| Nishiuchi, M | 1 |
| Ihara, H | 1 |
| Fujimoto, N | 1 |
| Shinji, Y | 1 |
| Górriz, JL | 1 |
| Pallardó, LM | 1 |
| Sarrión, A | 1 |
| Sánchez, J | 1 |
| Rochera, A | 1 |
| Daoud, S | 1 |
| Garnier, JL | 1 |
| Chossegros, P | 1 |
| Chevallier, P | 1 |
| Dubernard, JM | 1 |
| Touraine, JL | 1 |
| Bellary, S | 1 |
| Schiano, T | 1 |
| Hartman, G | 1 |
| Black, M | 1 |
| Rostaing, L | 2 |
| Izopet, J | 2 |
| Baron, E | 1 |
| Duffaut, M | 2 |
| Puel, J | 2 |
| Durand, D | 2 |
| Gadano, AC | 1 |
| Mosnier, JF | 1 |
| Durand, F | 1 |
| Martinot-Peignoux, M | 1 |
| Marcellin, P | 1 |
| Degott, C | 1 |
| Belghiti, J | 1 |
| Erlinger, S | 1 |
| Benhamou, JP | 1 |
| Bernuau, JR | 1 |
| Hizawa, N | 1 |
| Kojima, J | 1 |
| Kojima, T | 1 |
| Sukoh, N | 1 |
| Yamaguchi, E | 1 |
| Kawakami, Y | 1 |
| Matsushima, T | 1 |
| Kliem, V | 1 |
| Eberhard, OK | 1 |
| Oldhafer, K | 1 |
| Schlitt, HJ | 1 |
| Behrend, M | 1 |
| Schaumann, D | 1 |
| Pichlmayr, R | 1 |
| Koch, KM | 1 |
| Brunkhorst, R | 1 |
| Lengyel, G | 1 |
| Tran, A | 1 |
| Benzaken, S | 1 |
| Yang, G | 1 |
| Schneider, S | 1 |
| Doglio, A | 1 |
| Rampal, A | 1 |
| Rampal, P | 1 |
| Thevenot, T | 1 |
| Mathurin, P | 1 |
| Moussalli, J | 1 |
| Perrin, M | 1 |
| Plassart, F | 1 |
| Blot, C | 1 |
| Opolon, P | 1 |
| Poynard, T | 1 |
| Berenguer, M | 1 |
| Prieto, M | 1 |
| Córdoba, J | 1 |
| Rayón, JM | 1 |
| Carrasco, D | 1 |
| Olaso, V | 1 |
| San-Juan, F | 1 |
| Gobernado, M | 1 |
| Mir, J | 1 |
| Berenguer, J | 1 |
| Cisterne, JM | 1 |
| Arnaud, C | 1 |
| Rumeau, JL | 1 |
| Ghobrial, RM | 1 |
| Colquhoun, S | 1 |
| Rosen, H | 1 |
| Hollis, P | 1 |
| Ponthieux, S | 1 |
| Pakrasi, A | 1 |
| Farmer, DG | 1 |
| Markman, JF | 1 |
| Markowitz, J | 1 |
| Drazan, K | 1 |
| Yersiz, H | 1 |
| Singer, J | 1 |
| Stribling, R | 1 |
| Arnout, W | 1 |
| Holt, CD | 1 |
| Goss, J | 1 |
| Imagawa, D | 1 |
| Seu, P | 1 |
| Goldstein, LI | 1 |
| Shackleton, CR | 1 |
| Martin, P | 1 |
| Busuttil, RW | 1 |
| Caccamo, L | 2 |
| Rossi, G | 2 |
| Gridelli, B | 1 |
| Maggi, U | 2 |
| Reggiani, P | 2 |
| Colledan, M | 1 |
| Aroldi, A | 1 |
| Lampertico, P | 1 |
| Elli, A | 1 |
| Lunghi, G | 1 |
| Tarantino, A | 1 |
| Montagnino, G | 1 |
| Colombo, M | 1 |
| Ponticelli, C | 1 |
| Vannelli, A | 1 |
| Gatti, S | 1 |
| Paone, G | 1 |
| Melada, E | 1 |
| Latham, L | 1 |
| Andreani, P | 1 |
| Delladetsima, JK | 1 |
| Boletis, JN | 1 |
| Makris, F | 1 |
| Psichogiou, M | 1 |
| Kostakis, A | 1 |
| Hatzakis, A | 1 |
| Delgado, J | 1 |
| Muñoz de Bustillo, E | 1 |
| Ibarrola, C | 1 |
| Colina, F | 1 |
| Morales, JM | 1 |
| Rodriguez, E | 1 |
| Aguado, JM | 1 |
| Fuertes, A | 1 |
| Gomez, MA | 1 |
| Marroni, CA | 1 |
| Hoppe, L | 1 |
| Diehl, JL | 1 |
| Leipnitz, I | 1 |
| Brandão, AB | 1 |
| Cassal, AP | 1 |
| Schlindwein, E | 1 |
| Zanotelli, ML | 1 |
| Cantisani, GP | 1 |
| Laria, G | 1 |
| Pisani, F | 1 |
| Palmieri, GP | 1 |
| Bellanova, G | 1 |
| Torri, E | 1 |
| Buonomo, O | 1 |
| Casciani, CU | 1 |
| Fischer, L | 1 |
| Sterneck, M | 1 |
| Gahlemann, CG | 1 |
| Malago, M | 1 |
| Rogiers, X | 1 |
| Broelsch, CE | 1 |
| Golioto, M | 1 |
| McGrath, K | 1 |
| Hunt, J | 1 |
| Gordon, FD | 1 |
| Lewis, WD | 1 |
| Pomfret, E | 1 |
| Pomposelli, JJ | 1 |
| Jenkins, RL | 1 |
| Khettry, U | 1 |
| Ribeiro, AR | 1 |
| Veronese, FV | 1 |
| Manfro, RC | 1 |
| Gonçalves, LF | 1 |
| Schoeman, MN | 1 |
| Liddle, C | 1 |
| Bilous, M | 1 |
| Grierson, J | 1 |
| Craig, PI | 1 |
| Batey, RG | 1 |
| Farrell, GC | 1 |
| Vogten, AJ | 1 |
| Kaplan, MM | 1 |
| Sandrini, S | 1 |
| Scolari, F | 1 |
| Savoldi, S | 1 |
| Brunori, G | 1 |
| Tardanico, R | 1 |
| Facchetti, F | 1 |
| Delaini, C | 1 |
| Cristinelli, L | 1 |
| Maiorca, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Cross-over Study Comparing the Effect of Sirolimus Versus Mycophenolate on Viral Load in Liver Transplant Recipients With Recurrent Chronic HCV Infection[NCT01134952] | Phase 4 | 11 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Comparison of Maintenance Treatment by Ribavirin to a Placebo, After an Initial One-year Treatment With Pegylated Interferon-α2a - Ribavirin Association in Hepatitis C Viral Recurrence After Liver Transplantation[NCT00151580] | Phase 3 | 200 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | 9 |
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | 13.8 |
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | -6.0 |
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | 1.2 |
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | -2.7 |
Percent change in HCV load determined 3 months after switch from MMF to SRL. (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | 15 |
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | -8.5 |
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | 23 |
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | 23 |
Percent change in HCV load determined 3 months after switch from SRL to MMF (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | -47 |
(NCT01134952)
Timeframe: 3 month
| Intervention | ng/ml (Mean) |
|---|---|
| MMF SRL Switch | 7.2 |
8 reviews available for azathioprine and Hepatitis C
| Article | Year |
|---|---|
De novo autoimmune hepatitis -is this different in adults compared to children?
Topics: Adult; Age Factors; Autoantibodies; Azathioprine; Child; Female; Graft Rejection; Hepatitis C; Hepat | 2018 |
Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil.
Topics: Azathioprine; Graft Rejection; Hepatitis C; Humans; Immunosuppressive Agents; Kidney; Liver Transpla | 2009 |
Immunosuppression and HCV recurrence after liver transplantation.
Topics: Azathioprine; Cyclosporine; Graft Survival; Hepatitis C; Humans; Immunosuppressive Agents; Liver Tra | 2012 |
Immunosuppression in HCV-positive liver-transplant recipients.
Topics: Adrenal Cortex Hormones; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2012 |
Immunosuppression and modulation in liver transplantation.
Topics: Azathioprine; Calcineurin Inhibitors; Glucocorticoids; Graft Rejection; Hepatitis C; Humans; Immunos | 2004 |
[Diagnosis and treatment of chronic active hepatitis].
Topics: Adrenal Cortex Hormones; Azathioprine; Chemical and Drug Induced Liver Injury; Chronic Disease; Hepa | 1984 |
Primary lymphoma of the esophagus in a chronically immunosuppressed patient with hepatitis C infection: case report and review of the literature.
Topics: Aged; Azathioprine; Esophageal Neoplasms; Hepatitis C; Humans; Immunosuppression Therapy; Immunosupp | 2001 |
Hepatitis non-A, non-B.
Topics: Animals; Antigen-Antibody Complex; Antigens, Viral; Azathioprine; Hepatitis Antibodies; Hepatitis C; | 1985 |
8 trials available for azathioprine and Hepatitis C
| Article | Year |
|---|---|
Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy.
Topics: Adolescent; Adult; Aged; Azathioprine; Biopsy; Child; Drug Therapy, Combination; Female; Graft Rejec | 2009 |
Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation.
Topics: Adult; Azathioprine; Cyclosporine; Female; Fibrosis; Graft Rejection; Hepatitis C; Humans; Immunosup | 2005 |
Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal; Azathioprine; Basiliximab; Cyclosporin | 2004 |
Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis.
Topics: Adult; Aged; Azathioprine; Drug Therapy, Combination; Female; Graft Rejection; Hepatitis C; Humans; | 2006 |
Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients.
Topics: Adult; Aged; Alanine Transaminase; Azathioprine; Base Sequence; Biopsy; Chronic Disease; Creatinine; | 1995 |
FK 506 in the treatment of steroid- and OKT3-resistant rejection in renal transplant recipients: reduced dosage and anti-infective prophylaxis.
Topics: Adult; Anti-Infective Agents; Azathioprine; Contraindications; Creatinine; Dose-Response Relationshi | 1996 |
A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients.
Topics: Antilymphocyte Serum; Azathioprine; Cyclosporine; Cytomegalovirus Infections; Drug Therapy, Combinat | 2000 |
Liver function tests in mycophenolate mofetil-treated hepatitis C virus-positive kidney allograft recipients.
Topics: Azathioprine; Brazil; Hepatitis C; Humans; Immunosuppressive Agents; Kidney Transplantation; Liver F | 2002 |
40 other studies available for azathioprine and Hepatitis C
| Article | Year |
|---|---|
Frequency of Hepatobiliary Manifestations and Concomitant Liver Disease in Inflammatory Bowel Disease Patients.
Topics: Adult; Azathioprine; Cholelithiasis; Colitis, Ulcerative; Crohn Disease; Cross-Sectional Studies; Fe | 2019 |
Hepatitis C Virus-Autoimmune Hepatitis Overlap Syndrome in an Adolescent.
Topics: Alanine Transaminase; Antibodies, Viral; Aspartate Aminotransferases; Autoantibodies; Azathioprine; | 2015 |
Liver transplantation for hepatitis B and C virus-related cirrhosis: mid-term results.
Topics: Azathioprine; Cyclosporine; Graft Survival; Hepatitis B; Hepatitis C; Humans; Immunoglobulins; Immun | 2010 |
Adult post-transplant lymphoproliferative disease in the liver graft in patients with recurrent hepatitis C.
Topics: Adolescent; Aged; Antibodies, Viral; Azathioprine; Cohort Studies; Cyclosporine; Drug Therapy, Combi | 2011 |
Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation.
Topics: Adolescent; Adult; Aged; Azathioprine; Biopsy; Cohort Studies; Collagen; Disease Progression; Female | 2013 |
Lone hepatitis C virus myocarditis responsive to immunosuppressive therapy.
Topics: Adult; Angiography; Azathioprine; Biopsy, Needle; Cohort Studies; Drug Administration Schedule; Elec | 2002 |
A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection.
Topics: Azathioprine; Creatinine; Cross-Over Studies; Cyclosporine; Female; Hepatitis C; Humans; Immunosuppr | 2004 |
Takayasu's arteritis and hepatitis C: a new association?
Topics: Adult; Antiviral Agents; Azathioprine; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Polyme | 2004 |
Steroid and azathoprine maintenance as the best regimen during recurrent hepatitis C?
Topics: Age Factors; Azathioprine; Glucocorticoids; Hepatitis C; Humans; Immunosuppressive Agents; Liver Tra | 2005 |
Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation.
Topics: Adult; Age Factors; Aged; Azathioprine; Cyclosporine; Drug Therapy, Combination; Female; Glucocortic | 2005 |
Amantadine monotherapy is ineffective in the treatment of hepatitis C virus recurrence in the post-liver transplantation setting.
Topics: Amantadine; Antiviral Agents; Azathioprine; Cyclosporine; Female; Hepatitis C; Humans; Immunosuppres | 2005 |
Disappearance of HCV after cessation of immunosuppression in a patient with ulcerative colitis and renal transplantation.
Topics: Azathioprine; Colitis, Ulcerative; Female; Hepacivirus; Hepatitis C; Humans; Immunosuppression Thera | 2005 |
Retrospective study of the effects of cyclosporine in comparison with azathioprine on renal transplant recipients infected with hepatitis C virus.
Topics: Adult; Azathioprine; Cadaver; Cyclosporine; Drug Therapy, Combination; Female; Graft Survival; Hepat | 2006 |
[Fatal Sweet syndrome associated to chronic idiopathic systemic inflammatory response syndrome].
Topics: Aged; Anti-Inflammatory Agents; Azathioprine; Biopsy; Chronic Disease; Colchicine; Fatal Outcome; Fe | 2007 |
[Fibrosing alveolitis with hepatitis C-related cryoglobulinemia].
Topics: Azathioprine; Bronchoalveolar Lavage; Cryoglobulinemia; Cryoglobulins; Glucocorticoids; Hepatitis C; | 2008 |
[Therapy of chronic hepatitis (author's transl)].
Topics: Azathioprine; Chronic Disease; Drug Therapy, Combination; Hepatitis B; Hepatitis B Antibodies; Hepat | 1980 |
Evidence for hepatitis B and other virus infection in HBsAg-negative chronic active hepatitis.
Topics: Adult; Azathioprine; Chronic Disease; Female; Fluorescent Antibody Technique; Hepatitis; Hepatitis B | 1980 |
Long-term impact of hepatitis virus infection on kidney transplant recipients and a pilot study of the effects of interferon alpha on chronic hepatitis C.
Topics: Azathioprine; Cyclosporine; Follow-Up Studies; Graft Survival; Hepatitis B; Hepatitis C; Humans; Int | 1995 |
Hepatitis C virus infection in renal transplant recipients: prognostic significance of chronic transaminase elevation.
Topics: Actuarial Analysis; Adolescent; Adult; Analysis of Variance; Azathioprine; Biomarkers; Chi-Square Di | 1995 |
Hepatitis C virus infection in renal transplantation.
Topics: Azathioprine; Cyclosporine; Hepatitis C; Humans; Kidney Transplantation; Liver; Pancreas Transplanta | 1995 |
Chronic hepatitis with combined features of autoimmune chronic hepatitis and chronic hepatitis C: favorable response to prednisone and azathioprine.
Topics: Adult; Aged; Autoimmune Diseases; Azathioprine; Drug Therapy, Combination; Female; Hepatitis C; Hepa | 1995 |
alpha-Interferon-induced rejection of a hepatitis C virus-infected liver allograft tolerated with a low dosage immunosuppressive regimen.
Topics: Azathioprine; Chronic Disease; Cyclosporine; Female; Graft Rejection; Hepatitis C; Humans; Immunosup | 1995 |
A patient with chronic hepatitis C who simultaneously developed interstitial pneumonia, hemolytic anemia and cholestatic liver dysfunction after alpha-interferon administration.
Topics: Anemia, Hemolytic, Autoimmune; Azathioprine; Cholestasis, Intrahepatic; Female; Hepatitis C; Humans; | 1994 |
[Therapeutic principles after liver transplantation].
Topics: Azathioprine; Cyclosporine; Female; Hepatitis B; Hepatitis C; Hepatitis D; Humans; Immunosuppressive | 1996 |
Chronic hepatitis C and autoimmunity: good response to immunosuppressive treatment.
Topics: Aged; Autoantibodies; Autoimmune Diseases; Azathioprine; Chronic Disease; Female; Hepatitis C; Human | 1997 |
Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin.
Topics: Adult; Aged; Anemia; Antiviral Agents; Azathioprine; Chronic Disease; Contraindications; Drug Therap | 1997 |
Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection.
Topics: Alanine Transaminase; Azathioprine; Cyclosporine; Drug Therapy, Combination; Female; Genome, Viral; | 1998 |
Is long-term chronic immunosuppression therapy detrimental in hepatitis C virus-positive renal transplant patients?
Topics: Adrenal Cortex Hormones; Antilymphocyte Serum; Azathioprine; Cyclosporine; Female; Hepacivirus; Hepa | 1998 |
Retransplantation for recurrent hepatitis C following tacrolimus or cyclosporine immunosuppression.
Topics: Azathioprine; Cyclosporine; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C; Humans; Immun | 1998 |
High-rate hepatitis and low-rate rejection induced late morbidity and mortality in long-term follow-up after liver transplantation.
Topics: Adolescent; Adult; Azathioprine; Child; Child, Preschool; Cyclosporine; Drug Therapy, Combination; F | 1998 |
Long-term evolution of anti-HCV-positive renal transplant recipients.
Topics: Adult; Azathioprine; Blood Transfusion; Cyclosporine; Female; Follow-Up Studies; Graft Rejection; Gr | 1998 |
Hepatitis B and C virus-induced diseases and acute rejection after liver transplantation.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Azathioprine; Cyclosporine; Drug Therapy, | 1998 |
Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection.
Topics: Adult; Alanine Transaminase; Azathioprine; Biopsy; Cholestasis, Intrahepatic; Cyclosporine; Fatal Ou | 1999 |
Hepatitis C virus-related fibrosing cholestatic hepatitis after cardiac transplantation: is azathioprine a contributory factor?
Topics: Azathioprine; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Fatal Outcome; Hear | 1999 |
Diabetes mellitus and liver transplantation in adults.
Topics: Adult; Aged; Azathioprine; Blood Glucose; Brazil; Cyclosporine; Diabetes Mellitus; Hepatitis C; Huma | 1999 |
Effect of steroids amount on hepatitis C recurrence following orthtopic liver transplantation.
Topics: Azathioprine; Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; H | 1999 |
Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: influence of immunosuppressive regimens.
Topics: Adolescent; Adult; Aged; Azathioprine; Disease Progression; Female; Hepatitis C; Humans; Immunosuppr | 2001 |
Chronic non-A, non-B hepatitis: lack of correlation between biochemical and morphological activity, and effects of immunosuppressive therapy on disease progression.
Topics: Adult; Aged; Azathioprine; Biopsy; Female; Fibrosis; Follow-Up Studies; Hepatitis C; Hepatitis, Vira | 1990 |
Chronic liver diseases: current therapeutic options.
Topics: Adrenal Cortex Hormones; Autoimmune Diseases; Azathioprine; Cholangitis, Sclerosing; Chronic Disease | 1989 |
Liver disease in renal transplant patients treated with azathioprine or ciclosporin.
Topics: Azathioprine; Chemical and Drug Induced Liver Injury; Cyclosporins; Cytomegalovirus Infections; Fema | 1986 |